30results about How to "Low insoluble particulate content" patented technology

The invention discloses a platinum anticancer oxaliplatin composition, belonging to the technical field of medicines. The composition comprises oxaliplatin and sodium dihydrogen phosphate, wherein oxaliplatin is a crystal. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the specification. A new crystal form of oxaliplatin provided by the invention is different from the crystal structure of the prior art. Through experimental verification, the compound in the new crystal form has high purity, good flowability and stability and low impurity content, has low possibility of moisture absorption and is safe and reliable to apply clinically. Powder injections prepared by utilizing the compound in the new crystal form have good stability after undergoing compatibility with solvents, have low content of insoluble particles and are very suitable to apply clinically.

The invention relates to the technical field of production of a radix astragali seu hedysari injection and in particular discloses a refining method of a high-stability radix astragali seu hedysari injection solution and the radix astragali seu hedysari injection solution prepared by the refining method. The method comprises the following steps: carrying out water extraction and alcohol precipitation on radix astragali seu hedysari; after recycling ethanol from an obtained alcohol solution, carrying out water precipitation treatment; after concentrating an obtained water precipitation solution, cooling and filtering; adjusting the pH (Potential of Hydrogen) by utilizing an alkali until the pH is 9.0 to 10.0; heating and boiling; filtering and adding injection water into filtrate; adjusting the pH to be 7.3 to 7.5 by utilizing the alkali and filling; sterilizing to obtain the high-stability radix astragali seu hedysari injection solution. According to the method provided by the invention, a medicinal material foundation of the radix astragali seu hedysari is not limited, and impurities including tannin, proteins and the like are completely removed; meanwhile, saponins and flavones components are kept to the greatest extent; the prepared radix astragali seu hedysari injection solution has relatively high stability and also has the advantages of short production period, simplicity and convenience in operation and low production cost.

The invention relates to a ranitidine hydrochloride composition for treating gastric diseases, belonging to the technical field of medicines. The composition comprises ranitidine hydrochloride and anhydrous sodium carbonate, wherein ranitidine hydrochloride is a crystal. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the specification. A new crystal form of ranitidine hydrochloride provided by the invention is different from the crystal structure of the prior art. Through experimental verification, the compound in the new crystal form has high purity, good flowability and stability and low impurity content, has low possibility of moisture absorption and is safe and reliable to apply clinically. Powder injections prepared by utilizing the compound in the new crystal form have good stability after undergoing compatibility with solvents, have low content of insoluble particles and are very suitable to apply clinically.

The invention relates to a medicinal ranitidine hydrochloride composition for treating peptic ulcer. The composition comprises ranitidine hydrochloride and sodium dihydrogen phosphate. The ranitidine hydrochloride is a new crystal compound, the X-ray powder diffraction diagram, obtained by using Cu-K alpha rays for measuring, of the ranitidine hydrochloride is shown in figure 1, and the crystal structure of the pantoprazole sodium is different from that of ranitidine hydrochloride in the prior art. Experiments show that the new crystal compound is high in purity, good in flowability, good in stability, low in impurity content, less prone to moisture absorption and safe and reliable in clinical application; powder injection prepared by the new crystal compound is good in stability, good in stability after being combined with solvent, extremely low in insoluble particle content and quite suitable for clinical application.

The invention discloses an angiectasis medicine fasudil hydrochloride composition, and belongs to the technical field of medicine. Components of the composition include fasudil hydrochloride and anhydrous sodium carbonate. Fasudil hydrochloride is crystals. An X-ray powder diffraction pattern obtained by conducting measurement through Cu-K alpha rays is shown in figure 1. The new crystal form of the fasudil hydrochloride is different from a crystal form in the prior art, and through experimental verification, it is surprisingly found that the composition of the new crystal form is high in purity, mobility and stability, low in impurity content, not prone to moisture absorption and safe and reliable in clinical application and a powder injection manufactured through the composition of the new crystal form is high in stability, high in stability after being compatible with solvent, extremely low in insoluble particle content and quite suitable for clinical application.

The invention relates to a medicament oxaliplatin composition for treating cancers, belonging to the technical field of medicaments. The composition is prepared from oxaliplatin and anhydrous sodium carbonate; the oxaliplatin is crystals, and an X-ray powder diffraction pattern obtained by measurement with Cu-Ka rays is as shown in Figure 1. The novel crystal form of the oxaliplatin provided by the invention is different from a crystal form structure of the prior art. Experiments prove and find that the novel crystal form compound is high in purity, good in flowability, good in stability, low in impurity content, unlikely to absorb moisture, and safe and reliable in clinical application; a powder injection prepared from the novel crystal form compound is good in stability after matching with a solvent, extremely low in content of insoluble particles and very suitable for clinical application.

The invention discloses an anti-infective medicine of a cefamandole nafate composition, and belongs to the technical field of medicine. The composition comprises components including cefamandole nafate and sodium chloride; the cefamandole nafate is crystals; an X-ray powder diffraction pattern obtained through Cu-K alpha ray measurement is shown as figure 1. The novel crystal form of the cefamandole nafate provided by the invention is different from the crystal form structure in the prior art. Through experimental verification, users pleasantly and surprisedly find that the purity of a novel crystal form compound is high; the flowability is good; the stability is good; the polymer content is low; hygroscopicity is avoided; the clinical application is safe and reliable. Powder injections prepared from the novel crystal form compound have the advantages that the stability is good; the stability after the matching with solvents is good; the insoluble particulate content is extremely low; the powder injections are very suitable for clinical application.

The invention discloses an Ilaprazole sodium composition freeze-dried powder injection serving as medicine for treating stomach diseases, and belongs to the technical field of medicine. A composition comprises ilaprazole sodium and an excipient. The excipient is trehalose. The ilaprazole sodium is a novel-crystal-form compound, the X-ray powder diffraction pattern measured through Cu-Kalpha rays is shown as figure 1, and the ilaprazole sodium is different from ilaprazole sodium reported in the prior art; experiments show that the novel-crystal-form compound is high in purity, good in fluidity and stability, low in impurity content, not prone to absorbing moisture and safe and reliable in clinical application; the freeze-dried powder injection prepared through the novel-crystal-form compound is high in effect and bioavailability and good in stability; after compatibility is carried out on the powder injection and solvents, stability is good, the content of insoluble particles is quite small, and the powder injection is quite suitable for clinical application.

The invention discloses an ilaprazole sodium composition serving as medicine for treating digestive diseases, and belongs to the technical field of medicine. The composition is composed of ilaprazole sodium and sodium dihydrogen phosphate. The ilaprazole sodium is crystals, and the X-ray powder diffraction pattern measured through Cu-Kalpha rays is shown as figure 1. According to the ilaprazole sodium composition, the novel crystal form of the ilaprazole sodium is different from the crystal form structure in the prior art; due to experimental verification, it is found that the novel-crystal-form compound is high in purity, good in fluidity and stability, low in impurity content, not prone to absorbing moisture and safe and reliable in clinical application; powder-injections prepared through the novel-crystal-form compound are high in effect and bioavailability and good in stability; after the powder-injections are mixed with solvents, stability is good, the content of insoluble particles is quite small, and the powder-injections are quite suitable for clinical application.

The invention belongs to the technical field of medicines and relates to anti-tumor adjuvant drug calcium folinate composition. The composition comprises calcium folinate and anhydrous sodium carbonate, wherein the calcium folinate is crystal, and an X-ray powder diffraction diagram obtained through measurement by Cu-K alpha rays is shown in figure 1. The new crystal form of provided calcium folinate is different from a structure of a crystal form in the prior art. A test proves that compared with the prior art, the provided composition with the calcium folinate crystal form has good stability and low impurity content; by comparison with the prior art, the solubility and the flowability in water are remarkably improved, and the problems of poor water solubility of calcium folinate, poor stability and high content of related substances in the prior art are solved, convenience is provided for preparation of a preparation, and the medicine efficacy is greatly improved. A powder injection prepared from the new crystal-form composition has good stability, contains very few insoluble microparticles, is very suitable for clinic application and has good stability after being compatible with a solvent.

The invention discloses a hypotensive drug urapidil hydrochloride composition freeze-dried powder injection and belongs to the technical field of medicine. The composition comprises urapidil hydrochloride and an excipient. The excipient is trehalose, and the urapidil hydrochloride is a novel crystal form compound. The X-ray powder diffraction pattern obtained through Cu-K alpha ray measurement is shown in the picture 1 and is different from urapidil hydrochloride reported in the prior art. Tests prove that compared with the prior art, the solubility and mobility in water of the novel crystal form compound are obviously improved, and the freeze-dried powder injection prepared through the novel crystal form compound is good in stability, good in stability after being combined with a solvent, extremely low in insoluble particle content, and quite suitable for clinic application.

The invention discloses a medicine calcium folinate composition for treating leukocyte anemia, and belongs to the technical field of medicines. The composition is prepared form calcium folinate and sodium chloride; an X-ray powder diffraction pattern measured by a Cu-Kalpha ray is as shown in the figure 1. The novel crystal form of the calcium folinate disclosed by the invention is different from the crystal form structure in the prior art. Compared with the prior art, the calcium folinate composition disclosed by the invention is low in impurity content and better in stability; the solubility and the mobility of the calcium folinate compound are obviously improved in comparison with the prior art; convenience is provided for preparation of a preparation; the medicine effect is also greatly improved; a powder injection prepared from the novel crystal form compound is good in stability, and has good stability after being combined with a solvent; and the insoluble particle content is extremely low, so that the medicinal calcium folinate composition is very suitable for clinical application.

The invention discloses a medicinal fasudil hydrochloride composition for treating ischemic cerebrovascular diseases, which belongs to the technical field of medicines. The composition is prepared from fasudil hydrochloride and arginine, wherein the fasudil hydrochloride is a crystal, and an X-ray powder diffraction pattern, which is obtained by measurement of Cu-Kalpha rays, of the crystal, is as shown in figure 1. The new crystalline form of the fasudil hydrochloride provided by the invention is different from a crystalline structure in the prior art; by experimental verification, the medicinal fasudil hydrochloride composition is pleasantly found to have the advantages of high purity, good flowability, good stability, low content of impurities, low possibility of moisture absorption, and safety and reliability in clinical application; a power injection prepared from the new crystalline compound is good in stability, is good in stability after being matched with a solvent, is extremely low in content of insoluble particles, and is very suitable for clinical application.

The invention relates to a medicinal pantoprazole sodium composition for treating digestive system diseases and belongs to the technical field of medicine. The composition comprises pantoprazole sodium and arginine. The pantoprazole sodium is a new crystal compound, the X-ray powder diffraction diagram, obtained by using Cu-K alpha rays for measuring, of the pantoprazole sodium is shown in figure 1, and the crystal structure of the pantoprazole sodium is different from that of pantoprazole sodium in the prior art. Experiments show that the new crystal compound is high in purity, good in flowability, good in stability, low in impurity content, less prone to moisture absorption and safe and reliable in clinical application; powder injection prepared by the new crystal compound is good in stability, good in stability after being combined with solvent, extremely low in insoluble particle content and quite suitable for clinical application.

The invention relates to a medicine tropisetron hydrochloride composition for treating nausea and emesis and belongs to the technical field of medicines. The composition is prepared from tropisetron hydrochloride and anhydrous sodium carbonate, wherein the tropisetron hydrochloride is of a crystal and an X-ray powder diffraction pattern obtained by Cu-K alpha ray measurement is shown as a figure 1. A new crystal form of the tropisetron hydrochloride provided by the invention is different from a crystal form structure in the prior art; experimental verification is carried out to surprisedly find out that the compound with the new crystal form has high purity, good mobility, good stability and low impurity content, does not easily absorb moisture, and is safe and reliable in clinical application; a powder injection prepared from the compound with the new crystal form has good stability; the medicine tropisetron hydrochloride composition has good stability after being matched with a solvent, and the content of insoluble micro-particles is extremely low, so that the composition is very suitable for the clinical application.

The invention relates to a drug fasudil hydrochloride combination for treating cerebrovascular diseases and belongs to the technical field of pharmaceuticals. The combination is composed of fasudil hydrochloride and sodium chloride, the fasudil hydrochloride is crystal, and an X-ray powder diffraction diagram acquired by using Cu-Ka ray for measurement is shown as a figure 1. Novel crystal form of the fasudil hydrochloride is different from crystal form structure of the prior art, and experimental verification finds in surprise that the novel-crystal-form compound is high in purity, fluidity and stability, low in impurity content, less prone to moisture absorption and safe and reliable in clinical application; a powder injection prepared by utilizing the novel-crystal-form compound is high in stability after being combined with a solvent, extremely low in insoluble particle content and quite suitable for clinical application.

The invention relates to an anticancer oxaliplatin composition, and belongs to the technical field of medicine. The composition comprises oxaliplatin and sodium chloride, wherein oxaliplatin is crystal; the X-ray powder diffraction pattern, obtained through Cu-K[alpha] of oxaliplatin is shown in the figure 1. The novel crystal form of oxaliplatin is different from the conventional crystal form of oxaliplatin; tests show that the novel crystal form compound is high in purity, flowability and stability, and low in impurity content and hygroscopicity; the clinical application is safe and reliable; powder injection prepared from the novel crystal form compound is high in stability; the mixture of the powder injection and a solvent is high in stability and quite low in insoluble particle content. Therefore, the oxaliplatin composition is highly suitable for clinical application.

The invention relates to the technical field of production of a radix astragali seu hedysari injection and in particular discloses a refining method of a high-stability radix astragali seu hedysari injection solution and the radix astragali seu hedysari injection solution prepared by the refining method. The method comprises the following steps: carrying out water extraction and alcohol precipitation on radix astragali seu hedysari; after recycling ethanol from an obtained alcohol solution, carrying out water precipitation treatment; after concentrating an obtained water precipitation solution, cooling and filtering; adjusting the pH (Potential of Hydrogen) by utilizing an alkali until the pH is 9.0 to 10.0; heating and boiling; filtering and adding injection water into filtrate; adjusting the pH to be 7.3 to 7.5 by utilizing the alkali and filling; sterilizing to obtain the high-stability radix astragali seu hedysari injection solution. According to the method provided by the invention, a medicinal material foundation of the radix astragali seu hedysari is not limited, and impurities including tannin, proteins and the like are completely removed; meanwhile, saponins and flavones components are kept to the greatest extent; the prepared radix astragali seu hedysari injection solution has relatively high stability and also has the advantages of short production period, simplicity and convenience in operation and low production cost.

Belonging to the technical field of medicine, the invention relates to an antitumor drug oxaliplatin composition. The composition comprises: oxaliplatin and arginine. The oxaliplatin is crystal, and the X-ray powder diffraction pattern obtained by Cu-Kalpha ray measurement is shown as Figure 1. The new crystal form of oxaliplatin provided by the invention is different from the crystal structure of the prior art. Experimental verification finds that the new crystal form compound has the advantages of high purity, good fluidity, good stability, low impurity content, difficult absorption of moisture, and safe and reliable clinical application. The powder-injection obtained by the new crystal form compound has good stability, is stable after compatibility with a solvent, and has very low insoluble particle content, thus being very suitable for clinical application.

The invention discloses postoperative antiemetic medicine of a tropisetron hydrochloride composition, and belongs to the technical field of medicine. The composition consists of tropisetron hydrochloride and arginine, wherein the tropisetron hydrochloride is a crystal; an X-ray powder diffraction figure obtained through Cu-K alpha ray measurement is shown as the Figure 1. The novel crystal form of the tropisetron hydrochloride provided by the invention is different from the crystal form structure in the prior art; experimental verification pleasantly shows that the purity of the novel crystal compound is high; the liquidity is good; the stability is good; the impurity content is low; moisture cannot be absorbed; the clinical application is safe and reliable; powder injection prepared from the novel crystal form compounds has high stability; the stability is high after the composition is matched with solvents; the content of insoluble micro particles is very low; the lansoprazole composition is very suitable for clinic application.

The invention discloses a pharmaceutical ilaprazole sodium composition for treating gastric ulcer and belongs to the technical field of medicines. The pharmaceutical ilaprazole sodium composition is prepared from ilaprazole sodium and arginine, wherein the ilaprazole sodium is a crystal, as shown in Figure 1 of an X-ray powder diffraction diagram obtained through Cu-KAlpha ray measurement. The novel crystal-form ilaprazole sodium is different from a crystal-form structure in the prior art. It is found that the novel crystal-form compound is high in purity, good in liquidity and stability, low in impurity content and is safe and reliable in clinic application and does not easily absorb moisture though test verification. The injection powder prepared by utilizing the novel crystal-form compound is high in medicinal effect and bioavailability and good in stability, has good stability after being compatible with a solvent, is very low in insoluble particle content and is very suitable for clinic application.

The invention relates to an antibacterial drug-a cefamandole nafate composition, and belongs to the technical field of medicine. The composition is composed of cefamandole nafate and arginine, the cefamandole nafate is a crystal, and an X-ray powder diffraction pattern obtained by measuring with a Cu-K alpha ray is shown as figure 1. The antibacterial drug cefamandole nafate composition is different from a crystal structure of the prior art, and it is surprised to find that the crystal composition is high in purity, good in fluidity and stability, low in polymer content, not prone to absorbing moisture and safe and reliable in clinical application through experimental verification; a powder injection prepared by utilizing the novel crystal composition is good in stability, good in stability after being combined with solvent, extremely low in insoluble particle content, and very suitable for clinical application.

The invention discloses a medicine lansoprazole composition freeze-dried powder injection for treating digestive system diseases, and belongs to the technical field of medicine. The medicine lansoprazole composition comprises lansoprazole and excipient, wherein the excipient is mycose; the lansoprazole is a novel crystal form compound; the X-ray powder diffraction pattern measured by a Cu-K alpha ray is shown as the Figure 1; the lansoprazole is lansoprazole different from that reported in the prior art. Experiments prove that the lansoprazole crystal form compound provided by the invention does not contain impurities E; in addition, the contents of impurities A and impurities B are obviously reduced; the content change is small along with the prolonging of storage time; the fluidity is good; the dissolubility is obviously improved. The freeze-dried powder injection prepared from the novel crystal form compound has the advantages that the stability is good; the stability is good after the novel crystal form compound is matched with solvents; the insoluble particulate content is extremely low; the freeze-dried powder injection is very suitable for clinical application.

The invention relates to a medicinal urapidil composition for treating severe hypertension and belongs to the technical field of medicine. The composition comprises urapidil and arginine. The urapidil is a new crystal compound, the X-ray powder diffraction diagram, obtained by using Cu-K alpha rays for measuring, of the urapidil is shown in figure 1, and the crystal structure of the urapidil is different from that of urapidil in the prior art. According to experiments, compared with the prior art, the new crystal compound has the advantages that the compound is good in stability and extremely low in impurity I content, total impurity content is controlled in a relative low range, and the total impurity content change along with storage time is relatively small, and the solubility and flowability of the new crystal compound in water are improved evidently. Powder injection prepared by the new crystal compound is good in stability, good in stability after being combined with solvent, extremely low in insoluble particle content and quite suitable for clinical application.

The invention relates to the field of medicines and concretely relates to an aztreonam monohydrate and a preparation thereof. The aztreonam monohydrate has a structure shown in the formula (I). The invention also relates to a dosage form of the aztreonam monohydrate. The dosage form of the pharmaceutical composition is an injection preparation or an inhaled preparation. A stability test proves that the aztreonam monohydrate has good stability and especially has higher stability after matching and is suitable for clinical application.

The invention discloses a calcium folinate composition for adjuvant treatment of colon cancer and rectal cancer, and belongs to the technical field of medicine. The composition comprises calcium folinate and arginine, wherein the calcium folinate is a crystal; an X-ray powder diffraction pattern measured through using Cu-K alpha ray is described as the graph 1 (referring to the description). The novel crystal form of the calcium folinate provided by the invention is different from the crystal structure of the prior art, the test proves and discovers that compared with the prior art, the calcium folinate crystal composition provided by the invention has the following advantages: the stability is good, the content of impurities is low, and the solubility and fluidity in water are obviously improved; the problems that the calcium folinate in the prior art is poor in water solubility and stability and related substances are high in content are solved, so that convenience is provided for the preparation of a reagent, and the medicine effect is greatly improved; a powder injection prepared by using the novel crystal compound is good in stability, the stability is good after the powder injection is combined with a solvent, the content of insoluble particulates is extremely low, and the powder injection is quite suitable for clinical application.

The invention discloses an antidote calcium folinate composition for a folic acid antagonist, and belongs to the technical field of medicines. The composition comprises calcium folinate and sodium biphosphate, wherein calcium folinate is a crystal; the X-ray powder diffraction pattern of calcium folinate is measured by using Cu-K alpha rays and shown in figure 1. The new crystal structure of calcium folinate provided by the invention differs from the conventional crystal structure; tests prove that the composition, namely a calcium folinate crystal compound, has higher stability and a lower impurity content than that in the prior art; besides, compared with those in the prior art, the solubility and liquidity of the calcium folinate crystal compound in water are obviously improved, so that convenience is provided for preparation production and the medicine effect is greatly improved; a powder injection prepared by utilizing the new crystal compound is high in stability, and the stability is kept high after the new crystal compound is compatible with a solvent; the content of insoluble particles is extremely low; the new crystal compound is very suitable for clinical application.

The invention discloses a medicinal fasudil hydrochloride composition for treating cerebral ischemia, and belongs to the technical field of medicines. The composition is prepared from fasudil hydrochloride and sodium dihydrogen phosphate, wherein the fasudil hydrochloride is crystal, and the X-ray powder diffraction pattern obtained by using Cu-K alpha ray measurement is as shown in a diagraph 1. Different from the crystal form structure in the prior art, experimental verification surprisingly discovers that the novel crystal form of fasudil hydrochloride has the advantages of high purity, good fluidity, good stability, low impurity content, difficult moisture absorption and safe and reliable clinical application. A powder injection prepared by utilizing the novel crystal form compound has good stability after being mixed with a solvent, is low in content of insoluble particles, and is particularly suitable for clinical application.

The invention discloses a pantoprazole sodium composition for treating gastric diseases, belonging to the technical field of medicines. The composition is prepared from pantoprazole sodium and sodium chloride, wherein pantoprazole sodium is a crystal. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the specification. A new crystal form of pantoprazole sodium provided by the invention is different from the crystal structure of the prior art. Through experimental verification, the compound in the new crystal form has high purity, good flowability and stability and low impurity content, has low possibility of moisture absorption and is safe and reliable to apply clinically. Powder injections prepared by utilizing the compound in the new crystal form have good stability after undergoing compatibility with solvents, have low content of insoluble particles and are very suitable to apply clinically.

The invention relates to a medicine tropisetron hydrochloride composition for treating nausea and vomiting caused by chemotherapy and belongs to the technical field of medicines. The composition is composed of tropisetron hydrochloride and sodium chloride; the tropisetron hydrochloride is a crystal; an X-ray powder diffraction pattern obtained through Cu-K<alpha> ray measurement is shown in the figure 1 (shown in the description). The new crystal form of the tropisetron hydrochloride provided by the invention is different from that in the prior art, through experimental verification, that the new crystal form compound is high in purity, good in liquidity, good in stability, and low in impurity content, does not absorb moisture easily, and is safe and reliable in clinical application is pleasantly found, powder-injection prepared through the new crystal form compound is good in stability, and good in stability after being combined with a solvent, the content of insoluble particles is extremely low and the medicine tropisetron hydrochloride composition is very suitable for clinical application.